New Mexico
CNS clinical trials in New Mexico
19 CNS studies are recruiting participants at sites in 2 cities across New Mexico as of November 16, 2026, according to ClinicalTrials.gov.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Every New Mexico city with a recruiting study
By research area: Depression (7), Parkinson's Disease (6), Multiple Sclerosis (3), Migraine (2), Epilepsy (1).
Albuquerque (18), Shiprock (1).
The number after each city is how many studies have a recruiting site there. A study with sites in several cities is counted in each one.
Depression: recently updated in New Mexico
Basic details from each study's public record (the 12 most recently updated of 19). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Phase 2
- Ages 18 to 80
- All sexes
- Sponsor
- Reunion Neuroscience Inc
- Recruiting in
- Albuquerque
- Registry record
- NCT07002034 · updated
Study of ALTO-300 in MDD
- Phase 2
- Ages 18 to 70
- All sexes
- Sponsor
- Alto Neuroscience
- Recruiting in
- Albuquerque
- Registry record
- NCT05922878 · updated
Family Spirit Strengths
- No phase
- Ages 14 and older
- Female participants
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Recruiting in
- Shiprock
- Registry record
- NCT05836090 · updated
Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in New Mexico on ClinicalTrials.gov.
Parkinson's disease: recently updated in New Mexico
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Albuquerque
- Registry record
- NCT06841354 · updated
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Phase 3
- Ages 18 and older
- Female participants
- Sponsor
- Merck Sharp & Dohme LLC
- Recruiting in
- Albuquerque
- Registry record
- NCT06952504 · updated
A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease
- Phase 3
- Ages 50 to 85
- All sexes
- Sponsor
- Hoffmann-La Roche
- Recruiting in
- Albuquerque
- Registry record
- NCT07174310 · updated
A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease
- Phase 2
- Ages 40 to 80
- All sexes
- Sponsor
- Neuron23 Inc.
- Recruiting in
- Albuquerque
- Registry record
- NCT06680830 · updated
A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations
- Phase 2
- Ages 30 to 80
- All sexes
- Sponsor
- Appello Pharmaceuticals, Inc.
- Recruiting in
- Albuquerque
- Registry record
- NCT07432958 · updated
Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in New Mexico on ClinicalTrials.gov.
Multiple sclerosis (MS): recently updated in New Mexico
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
- Phase 3
- Ages 18 to 60
- All sexes
- Sponsor
- Zenas BioPharma (USA), LLC
- Recruiting in
- Albuquerque
- Registry record
- NCT07299019 · updated
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Phase 3
- Ages 40 to 70
- All sexes
- Sponsor
- Novartis Pharmaceuticals
- Recruiting in
- Albuquerque
- Registry record
- NCT06846281 · updated
Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in New Mexico on ClinicalTrials.gov.
Migraine: recently updated in New Mexico
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 to 75
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Recruiting in
- Albuquerque
- Registry record
- NCT07645924 · updated
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- TriGemX Bio, Inc.
- Recruiting in
- Albuquerque
- Registry record
- NCT07674654 · updated
Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in New Mexico on ClinicalTrials.gov.
Ask about studies in New Mexico
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
CNS Clinical Research does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections